{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:22:50Z","timestamp":1791296570738,"version":"4.1.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Among spliceosome component mutations, those involving SF3B1 are most frequent in myelodysplastic syndromes with ring sideroblasts (MDS-RS; \u223c 75% incidence) and SRSF2 in chronic myelomonocytic leukemia (\u223c 28% incidence). We recently reported on the lack of prognostic significance for SF3B1 mutations in both MDS-RS and primary myelofibrosis (PMF). In the current study, we examined the prevalence and prognostic relevance of SRSF2 mutations in PMF. Among 187 patients screened, 32 (17%) harbored SRSF2 monoallelic mutations affecting residue P95. Significant associations were demonstrated between SRSF2 mutations and advanced age (P &lt; .01), IDH mutations (P &lt; .01), and higher DIPSS-plus risk category (P = .03). SRSF2 mutations were associated with shortened overall (P &lt; .01) and leukemia-free (P &lt; .01) survival; the adverse effect on survival was independent of DIPSS-plus (P = .01; HR = 1.9; 95% CI, 1.1-3.0) and IDH mutations (P &lt; .01; HR = 2.3; 95% CI, 1.4-3.8). In conclusion, SRSF2 mutations are relatively common in PMF, cluster with IDH mutations, and are independently predictive of poor outcome.<\/jats:p>","DOI":"10.1182\/blood-2012-05-429696","type":"journal-article","created":{"date-parts":[[2012,9,13]],"date-time":"2012-09-13T01:38:03Z","timestamp":1347500283000},"page":"4168-4171","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":156,"title":["SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival"],"prefix":"10.1182","volume":"120","author":[{"given":"Terra L.","family":"Lasho","sequence":"first","affiliation":[{"name":"Divisions of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thitina","family":"Jimma","sequence":"additional","affiliation":[{"name":"Divisions of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy M.","family":"Finke","sequence":"additional","affiliation":[{"name":"Divisions of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal","family":"Patnaik","sequence":"additional","affiliation":[{"name":"Divisions of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[{"name":"Hematopathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett P.","family":"Ketterling","sequence":"additional","affiliation":[{"name":"Cytogenetics, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[{"name":"Divisions of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"Divisions of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7367","key":"2019111808371787000_B1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia.","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"issue":"26","key":"2019111808371787000_B2","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.","volume":"365","author":"Wang","year":"2011","journal-title":"N Engl J Med"},{"issue":"15","key":"2019111808371787000_B3","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111808371787000_B4","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1182\/blood-2011-12-395087","article-title":"Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML.","volume":"119","author":"Hirabayashi","year":"2012","journal-title":"Blood"},{"issue":"14","key":"2019111808371787000_B5","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/blood-2011-12-399774","article-title":"Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.","volume":"119","author":"Makishima","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111808371787000_B6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.","volume":"44","author":"Quesada","year":"2012","journal-title":"Nat Genet"},{"issue":"4","key":"2019111808371787000_B7","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111808371787000_B8","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1182\/blood-2011-08-371096","article-title":"Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients.","volume":"118","author":"Tefferi","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111808371787000_B9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/leu.2011.253","article-title":"IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F.","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"issue":"19","key":"2019111808371787000_B10","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis.","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2019111808371787000_B11","first-page":"2811","article-title":"Prognostic impact of EZH2 and ASXL1 mutation in myelofibrosis [abstract].","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"1","key":"2019111808371787000_B12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the Mayo Clinic experience.","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"2019111808371787000_B13","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/leu.2011.161","article-title":"Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients.","volume":"25","author":"Pardanani","year":"2011","journal-title":"Leukemia"},{"issue":"5","key":"2019111808371787000_B14","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"issue":"5","key":"2019111808371787000_B15","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/leu.2011.320","article-title":"SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients.","volume":"26","author":"Lasho","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"2019111808371787000_B16","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2019111808371787000_B17","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111808371787000_B18","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/leu.2010.113","article-title":"IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"4","key":"2019111808371787000_B19","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"2019111808371787000_B20","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"15","key":"2019111808371787000_B21","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","article-title":"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.","volume":"119","author":"Thol","year":"2012","journal-title":"Blood"},{"issue":"19","key":"2019111808371787000_B22","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","article-title":"Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms reveals recurrent SRSF2 mutations which are associated with adverse outcome.","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"issue":"14","key":"2019111808371787000_B23","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1182\/blood-2011-12-400994","article-title":"Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.","volume":"119","author":"Damm","year":"2012","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/20\/4168\/1359572\/zh804612004168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/20\/4168\/1359572\/zh804612004168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T14:02:25Z","timestamp":1574085745000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/20\/4168\/30540\/SRSF2-mutations-in-primary-myelofibrosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,15]]},"references-count":23,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2012,11,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-05-429696","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,15]]}}}